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incidence and epidemiology
Almost one million (951 600) new cases of gastric cancer were
diagnosed globally in 2012, resulting in ∼723 100 deaths [1]. Of
these ∼140 000 cases and ∼107 000 deaths occurred in Europe
[2]. Gastric cancer displays signiﬁcant global variation in inci-
dence; the highest rates are seen in Eastern Asia, Eastern Europe
and South America, with lower rates in North America and
Western Europe. A gradual decline in the incidence of gastric
cancer has been observed in Western Europe and North
America over the past 60 years and more recent declines in
high-prevalence countries have also become apparent. This is
epidemiologically distinct from the relative increase in tumours
of the gastroesophageal junction, which are discussed in a separ-
ate guideline document.
Risk factors for gastric cancer include male gender (incidence
is twice as high), Helicobacter pylori infection, tobacco use, atro-
phic gastritis, partial gastrectomy and Ménétrier’s disease [3].
Regional variation in gastric cancer risk factors inﬂuences the
most common anatomical subsites of disease. Distal or antral
gastric cancers that are associated with H. pylori infection,
alcohol use, high-salt diet, processed meat and low fruit and
vegetable intake are more common in East Asia. Tumours of the
proximal stomach (cardia) are associated with obesity, and
tumours of the gastroesophageal junction are associated with
reﬂux and Barrett’s oesophagus and are more common in non-
Asian countries [4]. Gastric cancer demonstrates familial aggre-
gation in ∼10% of cases, and an inherited genetic predisposition
is found in a small proportion of cases (∼1%–3%); relevant syn-
dromes include hereditary non-polyposis colorectal cancer, fa-
milial adenomatous polyposis colorectal cancer, hereditary
diffuse gastric cancer (HDGC), gastric adenocarcinoma and
proximal polyposis of the stomach (GAPPS) and Peutz Jegher’s
syndrome [5, 6]. If a familial cancer syndrome such as HDGC is
suspected, referral to a geneticist for assessment is recom-
mended based on international clinical guidelines [V, B] [7].
diagnosis and pathology
Recommendation: Diagnosis should be made from a gastroscopic
or surgical biopsy reviewed by an experienced pathologist, and
histology should be reported according to the World Health
Organisation (WHO) criteria [IV, C].
Patients in Asian countries are frequently diagnosed with
gastric cancer at an earlier stage than in non-Asian countries.
In Japan and Korea, where the incidence of gastric cancer is
much higher than in Western countries, screening for gastric
cancer is routine. In patients who develop symptoms from an
underlying gastric cancer, these commonly include weight loss,
dysphagia, dyspepsia, vomiting, early satiety and/or iron deﬁ-
ciency anaemia.
Ninety per cent of gastric cancers are adenocarcinomas
(ACs), and these are subdivided according to histological
appearances into diffuse (undifferentiated) and intestinal
(well-differentiated) types (Lauren classiﬁcation). Recent large-
scale studies in molecular subtyping have deﬁned four sub-
types of gastric cancer across genomic, transcriptomic and
proteomic levels; however, these subtypes do not yet have any
impact on treatment [8]. These Clinical Practice Guidelines do
not apply to rarer gastric malignancies such as gastrointestinal
stromal tumours (GISTs), lymphomas and neuroendocrine
tumours.
If a diagnosis of gastric cancer is suspected, diagnosis should
be made from a gastroscopic or surgical biopsy reviewed by an
experienced pathologist, and histology should be reported
according to the WHO criteria [IV, C].
staging and risk assessment
Recommendation: Initial staging and risk assessment should
include physical examination, blood count and differential, liver
and renal function tests, endoscopy and contrast-enhanced com-
puted tomography (CT) scan of the thorax, abdomen ± pelvis
(Table 1) [V, A]. Laparoscopy is recommended for patients with
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resectable gastric cancer [III, B]. Multidisciplinary treatment
planning before any treatment is mandatory [IV, C].
Careful tumour staging is essential to ensure that patients are
appropriately selected for treatment interventions. The recom-
mended initial staging investigations are detailed in Table 1.
Identiﬁcation of malignant lymph nodes on CT: The follow-
ing characteristics are frequently demonstrated in malignant
lymph nodes detected on CT:
1) Short-axis diameter 6–8 mm in perigastric lymph nodes;
2) round shape;
3) central necrosis and
4) heterogeneous or high enhancement [9–11].
However, the sensitivity of CT for lymph node staging is vari-
able (62.5%–91.9% on systematic review), and global consensus
is lacking on speciﬁc diagnostic criteria [12].
Endoscopic ultrasound (EUS) is helpful in determining the
proximal and distal extent of the tumour and provides further
assessment of the T and N stage; however, it is less useful in
antral tumours [III, B]. EUS is more consistently accurate than
CT for the diagnosis of malignant lymph nodes: patterns asso-
ciated with malignancy on EUS include hypoechogenicity,
round shape, smooth, distinct margin and size >1 cm [13, 14].
Positron emission tomography (PET)-CT imaging may improve
staging by detecting involved lymph nodes or metastatic disease.
However, PET may not be informative in patients with mucin-
ous or diffuse tumours [III, B].
Laparoscopy ± peritoneal washings for malignant cells is
recommended in all stage IB–III gastric cancers which are con-
sidered potentially resectable, to exclude radiologically occult
metastatic disease; the beneﬁt may be greater for patients with
T3/T4 disease [III, B] [15, 16].
The TNM stage should be recorded according to the latest
edition of the American Joint Committee on Cancer (AJCC)/
Union for International Cancer Control (UICC) guidelines and
staging manual [17, 18] (Tables 2 and 3).
treatment planning
Multidisciplinary treatment planning before any treatment deci-
sion is mandatory. The core membership of the multidisciplin-
ary team should include surgeons, medical and radiation
oncologists, radiologists and pathologists, with other members
as available [IV, C].
management of local/locoregional
disease
Recommendation: Endoscopic resection is appropriate for selected
very early tumours [III, B]. For stage IB–III gastric cancer, radical
gastrectomy is indicated and perioperative therapy is recom-
mended for these patients [I, A]. Medically ﬁt patients should
undergo D2 resections in high-volume surgical centres [I, B].
surgery
Surgical resection of gastric cancer, speciﬁcally at early stages, is
potentially curative. However, the majority of patients still
relapse following resection, and therefore, combined modality
therapies are standard for ≥ Stage IB disease.
The extent of resection is determined by the preoperative
stage.
Endoscopic resection may be carried out for very early gastric
cancers (T1a) if they are clearly conﬁned to the mucosa, well-
differentiated, ≤2 cm and non-ulcerated [III, B]. The associated
lymph node metastatic risk in this group is virtually zero. Two
forms of endoscopic resection are practised; endoscopic
mucosal resection (EMR) is acceptable for lesions smaller than
10–15 mm with a very low probability of advanced histology
(Paris 0–IIa) [19]. However, European Society of
Gastrointestinal Endoscopy Guidelines recommend endoscopic
submucosal dissection (ESD) as the treatment of choice for
most gastric superﬁcial neoplastic lesions [IV, B] [19].
T1 tumours that do not meet the above mentioned criteria for
endoscopic resection require surgery, although less extensive
surgery than other gastric cancers (see below). Lymph node dis-
section for T1 tumours may be conﬁned to perigastric lymph
nodes and include local N2 nodes (D1+, with variation in nodal
groups dissected according to the site of cancer). Sentinel lymph
node mapping may further modify these approaches.
For stage IB–III gastric cancer, radical gastrectomy is indicated.
Subtotal gastrectomy may be carried out if a macroscopic prox-
imal margin of 5 cm can be achieved between the tumour and the
gastroesophageal junction. For diffuse cancers, a margin of 8 cm
is advocated. Otherwise, a total gastrectomy is indicated [III, A].
Perioperative therapy is recommended for these patients.
The extent of nodal dissection accompanying radical gastrec-
tomy has been extensively debated. D1 resection implies the
removal of the perigastric lymph nodes and D2 implies removal
of perigastric lymph nodes plus those along the left gastric,
common hepatic and splenic arteries and the coeliac axis (see
Table 1. Diagnostic and staging investigations in gastric cancer
Procedure Purpose
Full blood count Assess for iron deficiency anaemia
Renal and liver function Assess renal and liver function to
determine appropriate therapeutic
options
Endoscopy and biopsy Obtain tissue for diagnosis, histological
classification and molecular
biomarkers, e.g. HER2 status
CT thorax + abdomen ± pelvis Staging of tumour—to detect local/
distant lymphadenopathy and
metastatic disease or ascites
EUS Accurate assessment of T and N stage
in potentially operable tumours
Determine the proximal and distal
extent of tumour
Laparoscopy ± washings Exclude occult metastatic disease
involving peritoneum/diaphragm
PET, if available May improve detection of occult
metastatic disease in some cases
CT, computed tomography; EUS, endoscopic ultrasound; PET, positron
emission tomography
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Figure 1) [20]. The current UICC/AJCC TNM (seventh edition)
classiﬁcation recommends excision of a minimum of 15 lymph
nodes to allow reliable staging. In Asian countries, experience
from observational and randomised trials demonstrates that D2
dissection leads to superior outcomes compared with D1 resec-
tion [II, B]. In Western countries, a Dutch [21], an MRC [22]
and a recent Italian [23] trial failed to demonstrate any initial
survival advantage with D2 resection, although the Italian study
suggested a trend towards a beneﬁt in disease-speciﬁc survival
for patients with T2–T4 lymph node-positive cancers treated
with D2 resection [23]. Long-term (15-year) follow-up from the
Dutch trial demonstrated fewer locoregional recurrences and
gastric cancer-related deaths with D2 resection; however, this
was offset slightly by an increase in postoperative mortality and
morbidity [24]. A recent review of the quality of lymph node
dissection in the same study also suggests that non-compliance
in the D2 resection group may have obscured a signiﬁcant dif-
ference in survival between the randomised groups; this has also
been suggested for the recent Italian study [23].
Consensus opinion is that, in Western countries, medically ﬁt
patients should undergo D2 dissection that is carried out in spe-
cialised, high-volume centres with appropriate surgical expertise
and postoperative care [I, B] [25–27]. As a result, perioperative
outcome has become standardised with morbidity and mortality
rates of 15% and 3.0%, respectively [23, 28]. The concept of
‘enhanced recovery’ encompasses all aspects of optimal peri-
operative care for the patient undergoing gastrectomy; guidance
is provided by relevant Enhanced Recovery After Surgery
(ERAS®) Society guidelines on this topic [29].
Table 2. TNM staging of gastric cancer as per AJCC, 7th edition [17, 18]
Primary tumour (T) Regional lymph nodes (N) Distant metastasis (M)
TX Primary tumour cannot be assessed NX Regional lymph node(s)
cannot be assessed
M0 No distant metastasis
T0 No evidence of primary tumour N0 No regional lymph node
metastasis
M1 Distant metastasis or positive
peritoneal cytology
Tis Carcinoma in situ: intraepithelial tumour without invasion of
the lamina propria
N1 Metastasis in 1–2 regional
lymph nodes
T1a Tumour invades the lamina propria or the muscularis mucosae N2 Metastasis in 3–6 regional
lymph nodes
T1b Tumour invades the submucosa N3 Metastasis in 7 or more
regional lymph nodes
T2 Tumour invades the muscularis propria N3a Metastasis in 7–15 regional
lymph nodes
T3 Tumour penetrates the subserosal connective tissue without
invasion of the visceral peritoneum or adjacent structuresa
N3b Metastasis in 16 or more
regional lymph nodes
T4 Tumour invades the serosa (visceral peritoneum) or adjacent
structuresb
T4a Tumour invades the serosa (visceral peritoneum)
T4b Tumour invades adjacent structuresb
Edge et al. [18]. Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, IL, USA. The original source for this material is
the AJCC Cancer Staging Handbook, 7th edition (2010) published by Springer Science and Business Media LLC, www.springer.com.
aT3 tumours also include those extending into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the
visceral peritoneum covering these structures.
bAdjacent structures include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine and retro-
peritoneum.
Table 3. Anatomic stage/prognostic groups as per AJCC, 7th
edition [17, 18]
Stage grouping T stage N stage M stage
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IB T2 N0 M0
T1 N1 M0
Stage IIA T3 N0 M0
T2 N1 M0
T1 N2 M0
Stage IIB T4a N0 M0
T3 N1 M0
T2 N2 M0
T1 N3 M0
Stage IIIA T4a N1 M0
T3 N2 M0
T2 N3 M0
Stage IIIB T4b N0–1 M0
T4a N2 M0
T3a N3 M0
Stage IIIC T4b N2–3 M0
T4a N3 M0
Stage IV Any T Any N M1
Edge et al. [18]. Used with the permission of the American Joint
Committee on Cancer (AJCC), Chicago, IL, USA. The original source
for this material is the AJCC Cancer Staging Handbook, 7th edition
(2010) published by Springer Science and Business Media LLC, www.
springer.com.
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Laparoscopic surgery has the potential beneﬁt of decreased
postoperative morbidity and reduced recovery time. Although
concerns existed regarding the possibility of a reduced nodal
harvest with a laparoscopic approach, a recent meta-analysis
suggests that lymph node yields are comparable for both
approaches [30]. Trials from the Far East have reported equiva-
lent results to open surgery for distal gastrectomy, but there
remain some technical issues particularly for anastomosis for
total gastrectomy [31, 32]. Laparoscopic surgery is becoming
one of the recommended options for patients with early gastric
cancer; however, it remains to be shown whether laparoscopic
surgery can achieve the same results as open surgery in gastric
cancers requiring D2 lymphadenectomy. It may be that as tech-
niques predicting lymph node involvement develop, those with
negative nodes should be operated laparoscopically, whereas
those with predicted positive nodes would require open surgery.
perioperative chemotherapy
Recommendation: Perioperative (pre- and postoperative) chemo-
therapy with a platinum/ﬂuoropyrimidine combination is recom-
mended for patients with ≥Stage IB resectable gastric cancer [I, A].
The UK MRC MAGIC trial demonstrated an improvement in
5-year survival from 23% to 36% for patients with resectable
stage II and III gastric cancers treated with six cycles (three pre-
and three postoperative) of perioperative ECF chemotherapy
[epirubicin, cisplatin and 5-ﬂuorouracil (5-FU)] compared with
surgery alone [33]. A subsequent French trial has reported
similar results with the use of a 28-day regimen of perioperative
cisplatin and 5-FU [34]. The MAGIC trial recruited predomin-
antly patients with gastric cancers, whereas the French study was
composed of a majority of patients with proximal tumours.
Therefore, a perioperative treatment approach may be considered
evidence-based for both tumour subsites. An EORTC study in
which patients were randomised to surgery plus or minus bi-
weekly cisplatin (50 mg/m2) and 5-FU in the de Gramont style
also increased R0 resection rates in chemotherapy-treated
patients but closed early due to poor accrual and is not powered
to show a survival beneﬁt [35]. Perioperative chemotherapy has
therefore been widely adopted as a standard of care throughout
many parts of Europe [I, A]. Since capecitabine avoids the need
for an indwelling central venous access device and is non-inferior
to 5-FU in the advanced disease setting [36], capecitabine-con-
taining regimens can also be suggested in the perioperative
setting (as ECX: epirubicin, cisplatin, capecitabine, in preference
to ECF) [IV, C]. Also, other platinum/ﬂuoropyrimidine doublets
or triplets may be considered; in particular, oxaliplatin may
replace cisplatin [as EOX (epirubicin, oxaliplatin, capecitabine)];
it is non-inferior to ECX in the metastatic setting [36]).
The effect of dose intensiﬁcation (e.g. with taxanes) of peri-
operative chemotherapy in gastric cancer remains unclear. In oe-
sophageal and gastroesophageal junctional AC, intensiﬁcation of
preoperative chemotherapy from two cycles of cisplatin and cape-
citabine (CX) to four cycles of ECX resulted in improved patho-
logical response rates (secondary end point), but this did not
translate into an improvement in overall survival (OS) [37].
However, as this trial did not include gastric cancer patients or a
postoperative chemotherapy component, direct cross-trial com-
parisons are challenging. A study of the German AIO study group
investigating a perioperative FLOT regimen (ﬂuorouracil, leucov-
orin, oxaliplatin, docetaxel) versus ECF/X demonstrated higher
rates of pathological response for FLOT (15.6% versus 5.8%);
however, correlation with survival outcomes is awaited [38].
Based on these studies, it may be reasonable to use any ﬂuoro-
pyrimidine–platinum doublet or triplet before surgery, although
the strongest evidence is for cisplatin/ﬂuorouracil ± epirubicin
Gastric cancer
(Adenorcarcinoma)
Operable
stage T1NO
Preferred pathway
Consider endoscopic/
limited resection
Preoperative
chemotherapy
Surgery Adjuvant
chemoradiotherapy
Adjuvant
chemotherapy
HER2-negative:
Platinum+
fluoropyrimidine-based
doublet or triplet regimen
HER2-positive:
Trastuzumab
+ CF/CX
Consider clinical
trials of novel agents
Second-line
chemotherapyPostoperative
chemotherapy
Surgery
Re-assess
Palliative
chemotherapy
Inoperable or
metastatic
Best supportive care if
unfit for treatment
Operable
stage >T1 NO
Figure 1. Gastric cancer treatment algorithm.
HER2, human epidermal growth factor receptor 2; CF, cisplatin and 5-ﬂuorouracil; CX, cisplatin and capecitabine
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combinations. Recommended treatment duration is 2–3 months.
There is no current evidence to support the use of perioperative
trastuzumab therapy or any other biologically targeted drug, in-
cluding anti-angiogenic compounds.
adjuvant treatment
Recommendation: For patients with ≥Stage IB gastric cancer who
have undergone surgery without administration of preoperative
chemotherapy (e.g. due to understaging before the initial decision
for upfront surgery), postoperative chemoradiotherapy (CRT) or
adjuvant chemotherapy is recommended [I, A]. For patients
having undergone preoperative chemotherapy, the addition of
postoperative radiotherapy (RT) has no added beneﬁt.
chemoradiotherapy. The North American Intergroup-0116
trial demonstrated that adjuvant therapy with 5-FU/leucovorin
(Q28) plus conventionally fractionated RT (45 Gy in 25
fractions) resulted in improved OS years compared with surgery
alone, (50% 3-year survival for patients treated with CRT versus
41% for those treated with surgery alone [39]). After 10 years of
follow-up, this OS improvement remains signiﬁcant [I, A] [40].
Therefore, this treatment approach is currently considered as
standard therapy in the USA, though it has not gained wide
acceptance in Europe due to concerns about potential late toxic
effects and the quality of surgery within the trial. Moreover,
>50% of patients underwent inadequate (less than D1)
lymphadenectomy, suggesting that postoperative CRT may be
(mainly) compensating for suboptimal surgery [II, B]. This is
supported by retrospective data from the Dutch D1D2 trial,
demonstrating that CRT reduces local recurrence rates following
D1 resection, but provides no beneﬁt in patients who have
undergone D2 resection [41]. However, other randomised and
non-randomised data suggest potential beneﬁts from
postoperative CRT even after optimal D2 dissection [I, B] [42–
45], and this is the subject of ongoing randomised trials.
Regarding patients who have had a microscopically incomplete
resection, a retrospective comparison of the Dutch D1D2 trial
has suggested signiﬁcant improvements in OS and local recur-
rence rates with use of CRT after an R1 resection, a ﬁnding that
has been conﬁrmed by other retrospective series [IV, B] [41, 46].
In current postoperative CRT regimens, RT should preferably
be given as a concomitant regimen of ﬂuoropyrimidine-based
CRT to a total dose of 45 Gy in 25 fractions of 1.8 Gy, 5 frac-
tions/week by intensity-modulated RT techniques [IV, A] [47].
The clinical target volume encompasses the gastric bed (with
stomach remnant when present), anastomoses and draining re-
gional lymph nodes [I, B] [44, 45].
adjuvant chemotherapy. The ACTS-GC trial evaluating adjuvant
chemotherapy with S-1 following D2 resection in Asian patients
demonstrated an OS beneﬁt for patients treated with adjuvant
chemotherapy [I, A] [48, 49]. The CLASSIC trial evaluated a
capecitabine–oxaliplatin doublet in a similar population and this
was associated with signiﬁcantly improved OS and disease-free
survival (DFS) [50, 51] compared with surgery alone.
However, none of sequential S1-paclitaxel, sequential tegafur
and uracil (UFT)-paclitaxel or UFT alone resulted in a superior
outcome (DFS as the primary end point) when compared with
single-agent, adjuvant S1 in a two by two randomised factorial
trial [52].
Historically, a greater beneﬁt has been noted with adjuvant
chemotherapy in Asian studies, and uptake of adjuvant chemo-
therapy in Europe for patients with resected gastric cancer
remains limited due to a perceived lack of beneﬁt and routine
use of perioperative chemotherapy. However, a large individual
patient-level meta-analysis of adjuvant chemotherapy in gastric
cancer has conﬁrmed a 6% absolute beneﬁt for 5-FU-based
chemotherapy, compared with surgery alone [hazard ratio (HR)
0.82, 95% conﬁdence interval (CI) 0.76–0.90; P < 0.001] in all
subgroups tested [I, A] [53]. However, as adjuvant chemother-
apy is also less well tolerated than neoadjuvant chemotherapy, a
perioperative approach is preferred if possible, so that more
patients can beneﬁt from systemic treatment even if the post-
operative component of treatment is unable to be delivered.
For adjuvant treatment following preoperative chemotherapy,
the preoperatively chosen regimen should be completed after re-
section for patients who are ﬁt for treatment, independent from
pathohistological ﬁndings and considerations. The addition of
postoperative RT has been shown to not improve survival in
patients receiving chemotherapy before and after curative-intent
surgery. Recently, the randomised, phase III CRITICS trial con-
cluded that patients undergoing chemotherapy followed by
surgery with curative intent had similar OS and progression-free
survival (PFS) regardless of whether they received chemother-
apy or CRT after surgery [54].
management of advanced/metastatic
disease
ﬁrst-line treatment
Recommendation: Doublet or triplet platinum/ﬂuoropyrimidine
combinations are recommended for ﬁt patients with advanced
gastric cancer [I, A].
Patients with inoperable locally advanced and/or metastatic
(stage IV) disease should be considered for systemic treatment
(chemotherapy), which has shown improved survival and
quality of life compared with best supportive care alone [I, A]
[55–57]. However, co-morbidities, organ function and perform-
ance status (PS) must always be taken into consideration [II, B].
In general, resection of the primary tumour is not recommended
in the palliative setting; however, a small number of patients with
initially unresectable locally advanced disease may be deemed op-
erable following a good response to systemic therapy.
Response to systemic treatments should normally be assessed
with interval imaging of the chest, abdomen and pelvis, mostly
with CT, although alternative imaging techniques may be used
if required to monitor known sites of disease (e.g. magnetic res-
onance imaging for bone lesions).
Doublet combinations of platinum and ﬂuoropyrimidines are
generally used, and there remains controversy regarding the utility
of triplet regimens. However, a meta-analysis has demonstrated sig-
niﬁcant beneﬁt from the addition of an anthracycline to a platinum
and ﬂuoropyrimidine doublet [58]. For anthracycline-based
triplets, the UK REAL-2 trial demonstrated non-inferiority
between ECF, ECX, EOF (epirubicin, oxaliplatin, 5-FU) and EOX.
The EOX regimen was associated with numerically longer median
OS (11.2 versus 9.9 months, HR 0.80, 95% CI 0.66–0.97; P = 0.02)
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than ECF, without the need for an indwelling catheter and with
reduced rates of thromboembolism [59]. Additionally, a combined
analysis has demonstrated that capecitabine is associated with
improved OS, compared with infused 5-FU within doublet and
triplet regimens [I, A] [58].
Triplets containing taxanes are also an evidence-based treat-
ment choice for ﬁrst-line chemotherapy [60, 61]. In a phase III
randomised trial, the addition of docetaxel to 5-FU/cisplatin in
a 3-weekly regimen (DCF) was associated with improved OS,
but also added signiﬁcant toxic effects including increased rates
of febrile neutropaenia [I, C] [61]. A phase II randomised control
trial of a modiﬁed 2-weekly DCF regimen compared with original
DCF (with growth factor support) halted recruitment in the origin-
al DCF arm due to excessive toxicity; however, the study suggested
that a substantially modiﬁed DCF regimen was tolerable and effect-
ive [II, B] [62]. Several other studies have examined the efﬁcacy of
docetaxel, ﬂuoropyrimidine and oxaliplatin-containing regimens.
The FLOT regimen (ﬂuorouracil, leucovorin, oxaliplatin and doce-
taxel) resulted in a median PFS of 5.1 months and a median OS of
11 months in a small non-randomised study [63]. An almost iden-
tical regimen used in a randomised phase II trial resulted in en-
couraging median PFS and OS of 7.7 and 14.6 months,
respectively [II, B] [64]. As an alternative to platinum-based
therapy, irinotecan plus leucovorin and infusional 5-FU (FOLFIRI)
has been studied in both phase II trials and one phase III rando-
mised trial in the ﬁrst-line setting, and may be considered for
selected patients [60, 65].
See the metastasectomy section for surgery in stage IV gastric
cancer.
elderly patients with gastric cancer
Elderly patients with gastric cancer are under-represented in clin-
ical trials, and there are few randomised data in this setting.
Regimens that have been speciﬁcally addressed in phase II trials
in elderly patients with comparable survival results include cape-
citabine and oxaliplatin, FOLFOX (leucovorin, 5-FU and oxali-
platin), single-agent capecitabine and S1 (in Asian patients) [III,
B] [66–68]. A phase II trial investigated the miniDOX (docetaxel,
oxaliplatin and capecitabine) regimen in primarily older patients
and also recruited patients with other poor prognostic markers
(PS2, weight loss 10%–25%). This regimen was associated with
survival comparable to good prognostic groups; however, toxicity
was also prominent [69]. In addition, a meta-analysis of three
phase III trials comparing patients ≥70 years with younger
patients demonstrated no differences in response rates or OS
between the two patient groups [II, B] [70]. In the perioperative
setting, a German study compared the doublet FLO (infusional
5-FU, leucovorin and oxaliplatin) and the FLOT regimens in 44
elderly gastric cancer patients [71]. Although the FLOT regimen
was associated with a trend towards improved PFS, it was also
associated with increased toxicity [II, B]. Furthermore, in the
MAGIC trial, there was no evidence of heterogeneity of treatment
effect for patients over the age of 70 [33]. However, it must be
considered that all patients included in these analyses were clinic-
al trial participants, which may not reﬂect patients treated in a
community setting. When making a decision regarding chemo-
therapy, the functional age of the patient must also be considered,
as co-morbidities and PS may have an equal effect on tolerance of
chemotherapy as age. Geriatric assessment may be helpful before
initiating treatment of older patients.
second- and further-line treatment
Recommendation: Second-line chemotherapy with a taxane (doc-
etaxel, paclitaxel), or irinotecan, or ramucirumab as single agent
or in combination with paclitaxel is recommended for patients
who are of PS 0–1 [I, A].
In patients of adequate PS, second-line treatment is associated
with proven improvements in OS and quality of life compared
with best supportive care, with treatment options including iri-
notecan, docetaxel or paclitaxel, if not used before [I, A] [72–
75]. A randomised phase III trial directly comparing weekly
paclitaxel with irinotecan has demonstrated similar efﬁcacy for
both regimens [I, A] [76].
The anti-VEGFR-2 monoclonal antibody ramucirumab has
shown activity in two randomised phase III trials. As a single
agent it is associated with a survival beneﬁt comparable to cyto-
toxic chemotherapy in the second-line setting [I, A], whereas
ramucirumab in addition to paclitaxel is associated with a sur-
vival beneﬁt compared with paclitaxel alone [I, A] [77, 78].
Alternatively, in patients with disease progression >3 months fol-
lowing ﬁrst-line chemotherapy, it may be appropriate to consider a
rechallenge with the same drug combination as an additional treat-
ment option [IV, C] [79]. In patients with symptomatic, locally
advanced or recurrent disease, hypo-fractionated RT is an effective
and well-tolerated treatment modality that may palliate bleeding,
obstructive symptoms or pain [III, B] [80].
Treatment options may be used sequentially in second and
third line, but there is no clear evidence for a beneﬁt beyond
second line treatment.
personalised medicine and targeted
therapy
Recommendation: Trastuzumab is recommended in conjunction
with platinum and ﬂuoropyrimidine-based chemotherapy for
patients with HER2-positive advanced gastric cancer [I, A].
Gastric cancers have been demonstrated to be highly molecu-
larly diverse and may be driven by a number of different genetic
and epigenetic abnormalities. Four subtypes of gastric cancer
have recently been described in The Cancer Genome Atlas;
these are the Epstein Barr Virus, microsatellite instability (MSI)
high, genomically stable and chromosomal instability (CIN)
subtypes [8]. Each subtype is enriched for selected molecular ab-
normalities, with some overlap. In particular, the CIN subtype
is enriched for copy number changes in key receptor tyrosine
kinase oncogenes such as HER2, EGFR, FGFR2 and MET.
These ﬁndings have potentially important therapeutic implica-
tions as oncologists attempt to target the key pathways driving
the tumour in each individual patient.
In HER2-positive gastric cancer (10%–15% of cases), the
phase III ToGA trial demonstrated clinically and statistically sig-
niﬁcant improvements in response rate, PFS and OS with the
addition of trastuzumab to a cisplatin/ﬂuoropyrimidine doublet
(median OS 13.8 versus 11.1 months, HR 0.74, 95% CI 0.60–
0.91; P = 0.0048) [I, A] [81]. The beneﬁts of trastuzumab were
even more marked in the traditionally deﬁned HER2-positive
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subgroup with immunohistochemistry (IHC) 2+/FISH+
tumours, or IHC 3+ tumours. In these patients, the median OS
was improved from 11.8 to 16.0 months (HR 0.65, 95% CI 0.51–
0.83). Following the ToGA trial results, trastuzumab was
licensed in Europe for use in HER2-positive disease (IHC3+ or
2+/FISH+) in combination with capecitabine or 5-FU and cis-
platin. This regimen now represents the standard of care for
these patients [I, A]. However, recent phase III randomised
trials targeting the EGFR and MET-HGF axes have not demon-
strated improvements in OS for anti-EGFR and anti-MET/HGF
therapies [82–85]. In contrast, emerging data from early phase
trials suggests that use of immunotherapies such as the PD-1
inhibitors pembrolizumab and nivolumab may result in durable
remissions for a proportion of patients with advanced gastric
cancer [86, 87]. The interaction between immunotherapy for
gastric cancer and other known biomarkers in gastric cancer
such as MSI requires further investigation.
A personalised medicine synopsis table is presented in
Table 4.
speciﬁc situations
metastasectomy
In general, patients with metastatic cancer do not beneﬁt from
resection of metastases. Uncontrolled case series have demon-
strated prolonged survival for selected patients undergoing liver
and lung metastasectomy and surgical removal of Krukenberg
tumours [V, C] [88–90]. The randomised REGATTA trial estab-
lished (in an Asian patient population) that gastrectomy in
patients with limited metastatic disease does not improve sur-
vival [I, A] [91]. Until further evidence is presented, both
gastrectomy and metastasectomy should be considered experi-
mental for patients with gastric cancer.
peritoneal metastases
Several small randomised trials in Asian patients have demon-
strated a signiﬁcant survival beneﬁt for adjuvant hyperthermic
intraperitoneal chemotherapy (HIPEC) in high-risk curatively
resected gastric cancer patients; however, these results have not
been validated in non-Asian patients [92, 93]. For patients with
advanced peritoneal metastases, data from randomised trials in
Asia also exist to support the use of cytoreductive surgery plus
HIPEC in selected patients [94]. However, randomised data are
lacking for non-Asian patients. A large French series demon-
strated a median survival of surgery plus HIPEC of 9.2 months,
with a 5-year survival rate of 13% for all patients and 23% for
those who had complete cytoreductive surgery [IV, C] [95].
Currently, this approach cannot be recommended outside the
context of clinical research.
signet cell tumours
Gastric AC associated with signet ring cells is associated with a
poor prognosis. Retrospective case series suggest that this gastric
cancer subtype may be less sensitive to chemotherapy and CRT
[IV] [96, 97]. However, evidence is insufﬁcient to support not
adopting standard chemotherapy or surgical approaches for
these patients.
follow-up, long-term implications and
survivorship
In the setting of operable gastric cancer, the complexity of treat-
ment frequently induces symptoms that adversely affect health-
related quality of life. A regular follow-up may allow investiga-
tion and treatment of symptoms, psychological support and
early detection of recurrence, though there is no evidence that it
improves survival outcomes [III, B] [98, 99].
Follow-up should be tailored to the individual patient and the
stage of the disease [V, B] [100]. Dietary support is recom-
mended for patients on either a radical or a palliative pathway
with reference to vitamin and mineral deﬁciencies [V, B] [101,
102].
New strategies for patient follow-up are currently undergoing
evaluation, including patient-led self-referral and services led by
clinical nurse specialists [103].
In the advanced disease setting, identiﬁcation of patients for
second-line chemotherapy and clinical trials requires regular
follow-up to detect symptoms of disease progression before sig-
niﬁcant clinical deterioration [IV, B].
If relapse/disease progression is suspected, then a clinical
history, physical examination and directed blood tests should be
carried out. Radiological investigations should be carried out in
patients who are candidates for further chemotherapy or RT
[IV, B].
The aggressive nature of gastric cancer and historically poor
outcomes even in the setting of operable disease mean that the
concept of survivorship is only now beginning to evolve. Long-
term implications, late effects of therapy and psychosocial impli-
cations of treatment have been poorly studied to date.
methodology
These clinical practice guidelines were developed in accordance
with the ESMO standard operating procedures for clinical prac-
tice guidelines development, http://www.esmo.org/Guidelines/
ESMO-Guidelines-Methodology. The relevant literature has
been selected by the expert authors. A summary of recommen-
dations is given in Table 1. Levels of evidence and grades of
Table 4. Personalised medicine synopsis table for lower
oesophageal and gastric cancer
Biomarker Method Use LOE,
GOR
HER2 Immunohistochemistry for
HER2 protein expression
or ISH for HER2 gene
amplification
Used to select
patients with
metastatic
disease for
treatment with a
trastuzumab-
containing
regimen
I, A
LOE, level of evidence; GOR, grade of recommendation; HER2, human
receptor growth factor receptor 2; ISH, in situ hybridisation.
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Table 5. Summary of recommendations
Incidence and epidemiology
• If a familial cancer syndrome such as HDGC is suspected, referral to a geneticist for assessment is recommended based on international clinical
guidelines [V, B]
Diagnosis and pathology
• Diagnosis should be made from a gastroscopic or surgical biopsy reviewed by an experienced pathologist, and histology should be reported according to
the WHO criteria [IV, C]
Staging and risk assessment
• Initial staging and risk assessment should include physical examination, blood count and differential, liver and renal function tests, endoscopy and
contrast-enhanced CT scan of the thorax, abdomen ± pelvis [V, A]
• Laparoscopy is recommended for patients with resectable gastric cancer [III, B]
• Multidisciplinary treatment planning before any treatment is mandatory [IV, C]
• EUS is helpful in determining the proximal and distal extent of the tumour and provides further assessment of the T and N stage; however, it is less
useful in antral tumours [III, B]
• PET-CT imaging may improve staging by detecting involved lymph nodes or metastatic disease. However, PET may not be informative in patients with
mucinous or diffuse tumours [III, B]
• Laparoscopy ± peritoneal washings for malignant cells are recommended in all stage IB–III gastric cancers that are considered potentially resectable, to
exclude radiologically occult metastatic disease; the benefit may be greater for patients with T3/T4 disease [III, B]
Treatment planning
• Multidisciplinary treatment planning before any treatment decision is mandatory. The core membership of the multidisciplinary team should include
surgeons, medical and radiation oncologists, radiologists and pathologists, with other members as available [IV, C]
Management of local/locoregional disease
• Endoscopic resection is appropriate for selected early tumours [III, B]
• For stage IB–III gastric cancer, radical gastrectomy is indicated; perioperative therapy is recommended for these patients [I, A]
• Medically fit patients should undergo D2 resections in high-volume surgical centres [I, B]
Surgery
• Endoscopic resection may be carried out for very early gastric cancers (T1a) if they are clearly confined to the mucosa, well-differentiated, ≤2 cm and
non-ulcerated [III, B]
• European Society of Gastrointestinal Endoscopy Guidelines recommend ESD as the treatment of choice for most gastric superficial neoplastic lesions
[IV, B]
• For stage IB–III gastric cancer, radical gastrectomy is indicated. Subtotal gastrectomy may be carried out if a macroscopic proximal margin of 5 cm can
be achieved between the tumour and the gastroesophageal junction. For diffuse cancers, a margin of 8 cm is advocated. Otherwise, a total gastrectomy is
indicated [III, A]. Perioperative therapy is recommended for these patients
• In Asian countries, experience from observational and randomised trials demonstrates that dissection leads to superior outcomes compared with D1
resection [II, B]
• Consensus opinion is that, in Western countries, medically fit patients should undergo D2 dissection that is carried out in specialised, high-volume
centres with appropriate surgical expertise and postoperative care [I, B]
Perioperative chemotherapy
• Perioperative (pre- and postoperative) chemotherapy with a platinum and fluoropyrimidine combination is recommended for patients with ≥stage IB
resectable gastric cancer [I, A]
• Since capecitabine avoids the need for an indwelling central venous access device, and is non-inferior to 5-FU in the advanced disease setting,
capecitabine-containing regimens can also be suggested in the perioperative setting [IV, C]
Adjuvant treatment
• For patients with ≥stage IB gastric cancer who have undergone surgery without administration of preoperative chemotherapy, postoperative CRT or
adjuvant chemotherapy is recommended [I, A]
• Adjuvant therapy with 5-FU/leucovorin plus conventionally fractionated RT resulted in improved OS years compared with surgery alone. After 10 years
of follow-up, this OS improvement remains significant [I, A]
• Postoperative CRT may (mainly) be compensating for suboptimal surgery [II, B]. However, some data suggest potential benefits from postoperative CRT
event after optimal D2 dissection [I, B]
• In patients who have had a microscopically incomplete resection, significant improvements in OS and local recurrence rates with the use of CRT after an
R1 resection have been seen [IV, B]
• RT should preferably be given as a concomitant regimen of fluoropyrimidine-based CRT to a total dose of 45 Gy in 25 fractions of 1.8 Gy, 5 fractions/
week by intensity-modulated RT techniques [IV, A]. The clinical target volume encompasses the gastric bed, anastomoses and draining regional lymph
nodes [I, B]
Continued
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recommendation have been applied using the system given in
Table 6. Statements without grading were considered justiﬁed
standard clinical practice by the experts and the ESMO faculty.
This manuscript has been subjected to an anonymous peer-
review process.
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Table 5. Continued
• OS benefit has been demonstrated for patients treated with adjuvant chemotherapy [I, A]
• The benefit of 5-FU-based chemotherapy has been confirmed compared with surgery alone [I, A]
Management of advanced/metastatic disease
First-line treatment
• Doublet or triplet platinum/fluoropyrimidine combinations are recommended for fit patients with advanced gastric cancer [I, A]
• Patients with inoperable locally advanced and/or metastatic (stage IV) disease should be considered for systemic treatment (chemotherapy), which has
shown improved survival and quality of life compared with best supportive care alone [I, A]. However, comorbidities, organ function and PS must always
be taken into consideration [II, B]
• Capecitabine is associated with improved OS compared with infused 5-FU within doublet and triplet regimens [I, A]
• DCF in a 3-weekly regimen was associated with improved OS, but also added significant toxic effects including increased rates of febrile neutropaenia
[I, C]
Elderly patients with gastric cancer
• Regimens that have been specifically addressed in phase II trials in elderly patients with comparable survival results include capecitabine and oxaliplatin,
FOLFOX, single-agent capecitabine and S1 (in Asian patients) [III, B]
• The FLOT regimen is associated with a trend towards improved PFS but also with increased toxicity [II, B]
Second- and further-line treatment
• Second-line chemotherapy with a taxane (docetaxel, paclitaxel), or irinotecan, or ramucirumab as a single agent or in combination with paclitaxel is
recommended for patients who are of PS 0–1 [I, A]
• Similar efficacy has been demonstrated for weekly paclitaxel and irinotecan [I, A]
• In patients with disease progression >3 months following first-line chemotherapy, it may be appropriate to consider a rechallenge with the same drug
combination [IV, C]
• In patients with symptomatic locally advanced or recurrent disease, hypofractionated RT is an effective and well-tolerated treatment modality that may
palliate bleeding, obstructive symptoms or pain [III, B]
Personalised medicine and targeted therapy
• Trastuzumab is recommended in conjunction with platinum- and fluoropyrimidine-based chemotherapy for patients with HER2-positive advanced
gastric cancer [I, A]
Specific situations
Metastasectomy
• Gastrectomy in patients with limited metastatic disease does not improve survival [I, A]
Peritoneal metastases
• In patients with peritoneal metastases, the use of cytoreductive surgery plus HIPEC has been studied, but this approach cannot yet be recommended
outside the context of clinical research.
Follow-up, long-term implications and survivorship
• A regular follow-up may allow investigation and treatment of symptoms, psychological support and early detection of recurrence, though there is no
evidence that it improves survival outcomes [III, B]
• Follow-up should be tailored to the individual patient and the stage of the disease [V, B]
• Dietary support is recommended for patients on either a radical or a palliative pathway, with reference to vitamin and mineral deficiencies [V, B]
• In the advanced disease setting, identification of patients for second-line chemotherapy and clinical trials requires regular follow-up to detect symptoms
of disease progression before significant clinical deterioration [IV, B]
• If relapse/disease progression is suspected, then a clinical history, physical examination and directed blood tests should be carried out. Radiological
investigations should be carried out in patients who are candidates for further chemotherapy or RT [IV, B]
HDGC, hereditary diffuse gastric cancer; WHO, World Health Organisation CT, computed tomography; EUS, endoscopic ultrasound; PET-CT, positron
emission tomography-computed tomography; ESD, endoscopic submucosal dissection; 5-FU, 5-fluorouracil; CRT, chemoradiotherapy; RT, radiotherapy;
OS, overall survival; PS, performance status; DCF, docetaxel, cisplatin, 5-FU; FOLFOX, leucovorin, 5-FU and oxaliplatin; FLOT, fluorouracil, leucovorin,
oxaliplatin and docetaxel; PFS, progression-free survival; HER2, human epidermal growth factor receptor 2; HIPEC, hyperthermic intraperitoneal
chemotherapy; AC, adenocarcinoma.
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